Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Mirko Zoncape, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Mandy Sau-Wai Chan, Clemence M Canivet, Manuel Romero-Gomez, Vincent Wai-Sun Wong, Seung Up Kim, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):289-304. Published online November 11, 2025
Background/Aims Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE). However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results.
Methods This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs.
Results F3–F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.12) and high-FIB-4-high-LSM (aSHR 21.38) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately.
Conclusions Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.
Citations
Citations to this article as recorded by
Are FIB-4 and liver stiffness measurement interchangeable for HCC risk stratification in MASLD? Yimeng Zhou, Xue Meng JHEP Reports.2026; : 101852. CrossRef
Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index Theja Channapragada, Sarah Batra, Breianna L. Hummer, Vernon M. Chinchilli, Daniel Huang, Rohit Loomba, Ian R. Schreibman, Jonathan G. Stine Digestive Diseases and Sciences.2026; 71(2): 628. CrossRef
Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study Fajuan Rui, Yee Hui Yeo, Liang Xu, Qi Zheng, Xiaoming Xu, Wenjing Ni, Youwen Tan, Qing-Lei Zeng, Zebao He, Xiaorong Tian, Qi Xue, Yuanwang Qiu, Chuanwu Zhu, Weimao Ding, Jian Wang, Rui Huang, Yayun Xu, Yunliang Chen, Junqing Fan, Zhiwen Fan, Xiaolong Qi, eClinicalMedicine.2024; 68: 102419. CrossRef
Functional effects and mechanisms of Phyllanthus emblica fruit and gallic acid on metabolic diseases: Experimental evidence and clinical perspectives Xiaoling Gou, Yin Ding, Yamei Wu, Yiwen Tao, Yaqian Wang, Yue Wang, Jingye Liu, Mi Ma, Xianhua Zhou, Tsedien Nhamdriel, Gang Fan Food Bioscience.2024; 59: 104039. CrossRef
Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model Marwa Matboli, Ibrahim Abdelbaky, Abdelrahman Khaled, Radwa Khaled, Shaimaa Hamady, Laila M. Farid, Mariam B. Abouelkhair, Noha E. El-Attar, Mohamed Farag Fathallah, Manal S. Abd EL Hamid, Gena M. Elmakromy, Marwa Ali Lipids in Health and Disease.2024;[Epub] CrossRef
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associated with overnutrition and obesity, although it may be also found in lean or non-obese individuals. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all-cause mortality, liver-related mortality, and cardiovascular mortality among non-obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake, and unaccounted weight changes over time. Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass index increases in the obese state. Overall, non-invasive tests, such as the Fibrosis-4 index, NAFLD fibrosis score, and liver stiffness measurement, perform better in lean or non-obese patients compared to obese patients. Lifestyle intervention works in non-obese patients, and less amount of weight loss may be required to achieve similar results compared to obese patients. Pharmacological therapy in non-obese NAFLD patients may require special consideration and a different approach compared to obese patients.
Citations
Citations to this article as recorded by
Obesity-Induced Pancreas Lipotoxicity, Oxidative Stress and Inflammation: Protective and Therapeutic Effects of Bee Bread Zaida Zakaria, Zaidatul Akmal Othman, Joseph Bagi Suleiman, Wan Syaheedah Wan Ghazali, Mahaneem Mohamed Journal of the American Nutrition Association.2026; 45(1): 89. CrossRef
Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country Kim Sui Wan, Halizah Mat Rifin, Muhammad Fadhli Mohd Yusoff, Wah Kheong Chan, Kishwen Kanna Yoga Ratnam, Shubash Shander Ganapathy, Hamizatul Akmal Abd Hamid, Masni Mohamad, Nurain Mohd Noor, Feisul Mustapha, Noor Ani Ahmad Scientific Reports.2026;[Epub] CrossRef
Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals Giovani Schulte Farina, Bárbara Brambilla, Emanuelle Mendonça Pandolfo, Laura Kalil Nader Lazzaretti, Stéfano Mateus Schio Kuiava, Ana Maria Graciolli, Vitória Maria Kriger, Carlos Henrique Dal Bem Fistarol, Augusto Cardoso Sgarioni, Henrique Prataviera G World Journal of Hepatology.2026;[Epub] CrossRef
Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Annals of Hepatology.2026; : 102199. CrossRef
Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song Hepatology International.2025; 19(1): 181. CrossRef
Optimal BMI cutoff for lean MASLD/MetALD and adverse hepatic outcomes in East-Asian populations Byungyoon Yun, Juyeon Oh, Heejoo Park, Beom Kyung Kim, Jin-Ha Yoon European Journal of Internal Medicine.2025; 133: 141. CrossRef
Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China Ruya Zhu, Caicai Xu, Suwen Jiang, Jianping Xia, Boming Wu, Sijia Zhang, Jing Zhou, Hongliang Liu, Hongshan Li, Jianjun Lou European Journal of Medical Research.2025;[Epub] CrossRef
Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin–Lipid Conjugate-Based Nanoparticle Kyeong-Ju Lee, Seong-Bin Yang, Jae-Hyeon Lee, Bison Seo, Hyung-Sik Won, Jooho Park Pharmaceutics.2025; 17(4): 480. CrossRef
Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(10): 13647. CrossRef
Impact of the FIB4 Index on Pre-sarcopenia in Patients with Metabolic-dysfunction Associated Steatotic Liver Disease Hiroki Nishikawa, Tomohiro Nishikawa, Akira Fukuda, Kosuke Ushiro, Masahiro Matsui, Saori Onishi, Soo Ki Kim, Akira Asai Internal Medicine.2025; 64(21): 3078. CrossRef
Effects of organic and inorganic contaminants and their mixtures on metabolic health and gene expression in developmentally exposed zebrafish Roxanne Bérubé, Matthew K LeFauve, Aicha Khalaf, Darya Aminioroomi, Christopher D Kassotis Environmental Toxicology and Chemistry.2025; 44(7): 1923. CrossRef
Differential risk factors of fibrosis between lean and obese MAFLD Alaa M. Mostafa, Yasser Fouad, Yasmine Gaber, Shereen Abdel Alem, Ziyan Pan, Mohammed Eslam Clinical and Experimental Medicine.2025;[Epub] CrossRef
Linarin alleviates high-fat diet-induced hepatic steatosis by inhibiting PDE4D and activating the cAMP/PKA/CREB pathway Yang Xiao, Jiale Wang, Hao Zhang, Xingzhen Yang, Jinfeng Zhou, Yunpeng Zhou, Siqi Liu, Mengkuan Liu, Yi Wang, Yang Wang, Qichao Liao, Menglong Hou, Yi Hao, Shi Liu, Zupeng Luo, Shuang Zhang, Jingsu Yu, Lin Yu, Lei Zhou, Yixing Li, Gaopeng Li Free Radical Biology and Medicine.2025; 239: 116. CrossRef
Outcomes of Acute Pancreatitis in Lean Versus Non-lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: A Nationwide Analysis Prince Addo Ameyaw, Sarpong Boateng, Yussif Issaka, Erika Sandra Ackah, Amita Ashokkumar Kasar, Yazan A. Al-Ajlouni, Basile Njei Digestive Diseases and Sciences.2025; 70(12): 4311. CrossRef
Integrating Precision Medicine and Digital Health in Personalized Weight Management: The Central Role of Nutrition Xiaoguang Liu, Miaomiao Xu, Huiguo Wang, Lin Zhu Nutrients.2025; 17(16): 2695. CrossRef
Impact of genotyping (PTPN2, rs2542151) and (MBOAT7, rs641738) in prediction of fibrosis in Metabolic dysfunction- associated steatotic liver disease’ patients Shimaa Abdelsattar, Hiba S. Al-Amodi, Hala F. M. Kamel, Zeinab A. Kasemy, Ehab Darwish, Asmaa Mosbeh, Ayman A. Sakr, Hanaa M. Elgazzar, Mervat Abdelkareem, Mai Abozeid, Shimaa K. Zewain, Hanan M. Bedair, Sabry M. Abdelmageed Frontiers in Endocrinology.2025;[Epub] CrossRef
Beneficial effects of probiotic supplementation (Lactiplantibacillus plantarum Dad-13) on body weight, liver function, and liver histopathological features in non-alcoholic fatty liver disease (NAFLD) model Sprague-Dawley rats Rahmawati MINHAJAT, Hanan AFIFAH, Husni CANGARA, Mirna MUIS, Agussalim BUKHARI, Sitti WAHYUNI Bioscience of Microbiota, Food and Health.2025; 44(4): 290. CrossRef
Serum Extracellular Vesicles as Pathogenetic Signals in Obese and Lean Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Chi-Yi Chen, Che-Yu Hsu, Wei-Pang Chung, Hung-Yu Sun, Tzu-Ching Kao, Tzu-Yi Chen, Xing-Min Li, Wei-Lung Huang, Kung-Chia Young Metabolites.2025; 15(11): 746. CrossRef
The role of adipose tissue in liver fat accumulation: a sex-specific analysis in an exploratory cross-sectional study Jana Hoffmann, Jochen Schmidt, Jens Thiele, Stefan Kwast, Roberto Falz, Timm Denecke, Martin Busse, Hans-Jonas Meyer Lipids in Health and Disease.2025;[Epub] CrossRef
Impact of nonalcoholic fatty liver disease on the risk of gallbladder polyps in lean and non-obese individuals: A cohort study Nam Hee Kim, Ji Hun Kang, Hong Joo Kim Hepatobiliary & Pancreatic Diseases International.2024; 23(6): 573. CrossRef
Association between weight-adjusted waist index and non-alcoholic fatty liver disease: a population-based study Changhui Yu, Shiming He, Maobin Kuang, Chao Wang, Xin Huang, Guotai Sheng, Yang Zou BMC Endocrine Disorders.2024;[Epub] CrossRef
Triglycerides Mediate the Influence of Body Mass Index on Non-Alcoholic Fatty Liver Disease in a Non-Obese Chinese Population with Normal Low-Density Lipoprotein Cholesterol Levels Xixi Han, Jingwen Kong, Hemin Zhang, Yuan Zhao, Yafeng Zheng, Chao Wei Obesity Facts.2024; 17(2): 191. CrossRef
Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun Gut and Liver.2024; 18(2): 316. CrossRef
Association between nonalcoholic fatty liver disease and gallstone risk in nonobese and lean individuals Nam Hee Kim, Ji Hun Kang, Hong Joo Kim European Journal of Gastroenterology & Hepatology.2024; 36(7): 945. CrossRef
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping Shahid Habib World Journal of Gastrointestinal Pathophysiology.2024;[Epub] CrossRef
Cardiometabolic and Metabolic Profiles of Lean/Normal, Overweight and Obese Patients with Nonalcoholic Fatty Liver Disease Siyao Wang, Yong Zhang, Xiaoya Qi, Xiaoyang Xu Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 2027. CrossRef
Association between the cardiometabolic index and NAFLD and fibrosis Laisha Yan, Xiaoyan Hu, Shanshan Wu, Can Cui, Shunying Zhao Scientific Reports.2024;[Epub] CrossRef
Predictive Value of the Chinese Visceral Adiposity Index for Metabolic Dysfunction-Associated Fatty Liver Disease and Elevated Alanine Aminotransferase Levels in Nonobese Chinese Adults: A Cross-Sectional Study Zuohu Niu, Jialiang Chen, Huijing Wang, Rongrui Wang, Hongye Peng, Shaojie Duan, Shukun Yao Journal of Inflammation Research.2024; Volume 17: 3893. CrossRef
From MASLD to HCC: What's in the middle? Alessia Provera, Cristina Vecchio, Anteneh Nigussie Sheferaw, Ian Stoppa, Deepika Pantham, Umberto Dianzani, Salvatore Sutti Heliyon.2024; 10(15): e35338. CrossRef
Mitigating Effects of Tanacetum balsamita L. on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rositsa Mihaylova, Reneta Gevrenova, Alexandra Petrova, Yonko Savov, Dimitrina Zheleva-Dimitrova, Vessela Balabanova, Georgi Momekov, Rumyana Simeonova Plants.2024; 13(15): 2086. CrossRef
Comparison of Risk Factors Between Lean and Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals With Type 2 Diabetes: A Multicenter Study Weixia Sun, Yingqi Lv, Li Wang, Hekai Yu, He Yi, Yifan Wang, Jing Han, Yingzhao Liu, Congqing Miao, Jie Li, Yan Zhang, Mengying Wang, Lei Chen, Stephen J. Pandol, Ling Li Endocrine Practice.2024; 30(12): 1171. CrossRef
Understanding Insulin Resistance in NAFLD: A Systematic Review and Meta-Analysis Focused on HOMA-IR in South Asians Margeyi Mehta, Jigish Shah, Urvish Joshi Cureus.2024;[Epub] CrossRef
Liver Fibrosis in Some Patients with Non-Alcoholic Fatty Liver Disease: from Diagnosis to Prognosis Tatyana S. Krolevets, Maria A. Livzan, Maria I. Syrovenko Annals of the Russian academy of medical sciences.2024; 79(4): 293. CrossRef
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim Clinical and Molecular Hepatology.2024; 30(4): 989. CrossRef
An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease Shahid Habib, Andrew Johnson Exploration of Digestive Diseases.2024; : 459. CrossRef
Lactobacillus plantarum L11 and Lactobacillus reuteri LR: Ameliorate Obesity via AMPK Pathway Shukun Liang, Jintao Sun, Xinshu Gu, Ya Zhao, Xiumin Wang, Hui Tao, Zhenlong Wang, Yougang Zhong, Jinquan Wang, Bing Han Nutrients.2024; 17(1): 4. CrossRef
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy Wah-Loong Chan, Shi-En Chong, Felicia Chang, Lee-Lee Lai, Kee-Huat Chuah, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Wah-Kheong Chan Hepatology International.2023; 17(4): 870. CrossRef
Food Network Analysis in Non-Obese Patients with or without Steatosis Rossella Donghia, Pasqua Letizia Pesole, Sergio Coletta, Caterina Bonfiglio, Giovanni De Pergola, Sara De Nucci, Roberta Rinaldi, Gianluigi Giannelli Nutrients.2023; 15(12): 2713. CrossRef
Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B Yong‐Wen Leow, Wah‐Kheong Chan Journal of Viral Hepatitis.2023; 30(8): 712. CrossRef
Visceral fat: A key mediator of NAFLD development and progression Savita Bansal, Meenakshi Vachher, Taruna Arora, Bhupender Kumar, Archana Burman Human Nutrition & Metabolism.2023; 33: 200210. CrossRef
Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease—Oxidative Stress and Inflammation Relevance Madalina Andreea Robea, Ioana-Miruna Balmus, Irina Girleanu, Laura Huiban, Cristina Muzica, Alin Ciobica, Carol Stanciu, Carmen Diana Cimpoesu, Anca Trifan Medicina.2023; 59(9): 1614. CrossRef
Zebrafish as a Useful Model System for Human Liver Disease Nobuyuki Shimizu, Hiroshi Shiraishi, Toshikatsu Hanada Cells.2023; 12(18): 2246. CrossRef
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Eugene Han, Yong-ho Lee Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef
Associations of Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease With Cardiovascular Healthy Outcomes Wentao Wu, Wen Ma, Shiqi Yuan, Aozi Feng, Li Li, Haoxiao Zheng, Shuna Li, Ningxia He, Yuli Huang, Jun Lyu Journal of the American Heart Association.2023;[Epub] CrossRef
Background/Aims 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) variants were recently reported to have significantly lower odds of non-alcoholic fatty liver disease (NAFLD). This is a two-part study that aimed to evaluate the association of HSD17B13 variants with NAFLD and its histological severity, and to identify the association of the variants with clinical outcomes in a cohort of biopsy-proven NAFLD patients.
Methods Consecutive biopsy-proven NAFLD patients and controls without fatty liver were recruited for this study between 2009 and 2014. Genotyping for HSD17B13 variants was performed using rhAmp assays. A total of 165 patients with NAFLD were monitored up until August 2019. Clinical outcomes were recorded.
Results HSD17B13 rs72613567 TA allele and rs6834314 G allele were associated with lower odds of non-alcoholic steatohepatitis (NASH) in the overall cohort and among ethnic Chinese, but not among ethnic Malays or Indians (P<0.05). During a mean follow-up of 89 months, 32 patients (19.4%) experienced at least one clinical outcome (cardiovascular events, n=22; liver-related complications, n=6; extra-hepatic malignancy, n=5; and mortality, n=6). The rs72613567 homozygous TA allele and the rs6834314 homozygous G allele were independently associated with a lower incidence of liver-related complications (hazard ratio [HR], 0.004; 95% confidence interval [CI], 0.00–0.64; P=0.033 and HR, 0.01; 95% CI, 0.00–0.97; P=0.048, respectively) and were associated with lower grade of hepatocyte ballooning among the ethnic Chinese.
Conclusion HSD17B13 rs72613567 and rs6834314 variants were inversely associated with NAFLD and NASH, and were associated with lower incidence of adverse liver outcomes in a cohort of multi-ethnic Asian patients with NAFLD.
Citations
Citations to this article as recorded by
RNA-based drugs: current, imminent and possible therapeutic applications Sebastiano A. Torrisi, Federica Geraci, Lidia Diolosà, Angelina De Luca, Luca Falzone, Filippo Drago, Massimo Libra, Gian Marco Leggio Pharmacology & Therapeutics.2026; 277: 108958. CrossRef
Disease-driven loss of inactive HSD17B13 isoforms enhances enzymatic output in MASH and counters protective rs72613567:TA variant John Min, Mulugeta Seneshaw, Faridoddin Mirshahi, Hae-Ki Min, Arun J. Sanyal JHEP Reports.2026; 8(5): 101793. CrossRef
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management Karen Hei-Tung Lai, Vincent Wai-Sun Wong Singapore Medical Journal.2026;[Epub] CrossRef
The versatile interplay between steatotic liver disease and liver cancer Mohammad Rahbari, Albert Gris-Oliver, Pierluigi Ramadori, David Aicher, Daniela Sia, Nisar P. Malek, Rohit Loomba, Ramon Bataller, Josep M. Llovet, Mathias Heikenwälder Nature Reviews Cancer.2026;[Epub] CrossRef
Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis Limin Lin, Jiaming Lai, Ling Luo, Junzhao Ye, Bihui Zhong Annals of Hepatology.2025; 30(2): 101780. CrossRef
Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine Xiang Zhang, Kyong-Mi Chang, Jun Yu, Rohit Loomba
Annual Review of Pathology: Mechanisms of Disease
.2025; 20(1): 375. CrossRef
Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease Jun-Jie Wang, Xiao-Yuan Chen, Yi-Rong Zhang, Yan Shen, Meng-Lin Zhu, Jun Zhang, Jun-Jie Zhang Frontiers in Physiology.2025;[Epub] CrossRef
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina American Journal of Physiology-Cell Physiology.2025; 328(5): C1637. CrossRef
Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L Alimentary Pharmacology & Therapeutics.2025; 62(3): 244. CrossRef
Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis Arun J. Sanyal, Jorg Taubel, Prajakta Badri, Sarah Bond, Nune Makarova, Weizhi Zhao, Swati Duggal, Farshad Kajbaf, Benjamin A. Olenchock, John M. Gansner Journal of Hepatology.2025; 83(4): 838. CrossRef
The Distribution and Survival Association of Genetic Polymorphisms in Thai Patients with Hepatocellular Carcinoma According to Underlying Liver Disease Theint Cho Zin Aung, Bootsakorn Boonkaew, Maneerat Chayanupatkul, Kittiyod Poovorawan, Natthaya Chuaypen, Pisit Tangkijvanich Genes.2025; 16(7): 808. CrossRef
Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges Jingyuan Ma, Yanna Ma, Xing Wan, Junchen Li, Yunshu Zhang, Jifeng Liu, Yunhai Gao Frontiers in Endocrinology.2025;[Epub] CrossRef
17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population Bale Govardhan, V. Kulkarni Anand, Padaki Nagaraja Rao, P. Balachandran Menon, Sharma Mithun, Mitnala Sasikala, T.R. Sowmya, Sekaran Anuradha, C. Pawar Smita, D. Nageshwar Reddy, Vishnubhotla Ravikanth Journal of Clinical and Experimental Hepatology.2024; 14(4): 101371. CrossRef
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients Ernest A. Adeghate Expert Opinion on Pharmacotherapy.2024; 25(3): 223. CrossRef
Emerging roles of RNA‐binding proteins in fatty liver disease Oluwafolajimi Adesanya, Diptatanu Das, Auinash Kalsotra WIREs RNA.2024;[Epub] CrossRef
Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease? Adele Tulone, Grazia Pennisi, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Roberto Cannella, Francesco Mercurio, Salvatore Petta United European Gastroenterology Journal.2024; 12(5): 638. CrossRef
Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Kamonchanok Moonlisarn, Pornjira Somnark, Bootsakorn Boonkaew, Chalermarat Bunchorntavakul, Pisit Tangkijvanich Genes.2024; 15(11): 1370. CrossRef
Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology Camila Cristiane Pansa, Letícia Ramos Molica, Karen C. M. Moraes Scandinavian Journal of Gastroenterology.2023; 58(5): 521. CrossRef
Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba Alimentary Pharmacology & Therapeutics.2023; 57(1): 37. CrossRef
Geographical similarity and differences in the burden and genetic predisposition of NAFLD Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai‐Hung Wong, Leon A. Adams, Victor de Lédinghen, Silvia Sookoian, Vincent Wai‐Sun Wong Hepatology.2023; 77(4): 1404. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Seung Min Lee, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science Sven Thamm, Marina K. Willwacher, Gary E. Aspnes, Tom Bretschneider, Nicholas F. Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M. Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Ma Journal of Medicinal Chemistry.2023; 66(4): 2832. CrossRef
Comparison between obese and non-obese nonalcoholic fatty liver disease Wah-Kheong Chan Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases O. V. Smirnova, D. V. Lagutinskaya Meditsinskiy sovet = Medical Council.2023; (8): 119. CrossRef
Food Network Analysis in Non-Obese Patients with or without Steatosis Rossella Donghia, Pasqua Letizia Pesole, Sergio Coletta, Caterina Bonfiglio, Giovanni De Pergola, Sara De Nucci, Roberta Rinaldi, Gianluigi Giannelli Nutrients.2023; 15(12): 2713. CrossRef
Associations between genetic variants of HSD17B13 and fasting plasma glucose in Chinese children Ping-ping Zhang, Jie-yun Song, Li Li, Miao Xu, Hui Wang, Hai-jun Wang Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(9): 1778. CrossRef
Advances in genetic variation in metabolism-related fatty liver disease Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang Frontiers in Genetics.2023;[Epub] CrossRef
Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches Eirini Martinou, Marinos Pericleous, Irena Stefanova, Vasha Kaur, Angeliki M. Angelidi Diagnostics.2022; 12(2): 407. CrossRef
Therapeutic RNA-silencing oligonucleotides in metabolic diseases Algera Goga, Markus Stoffel Nature Reviews Drug Discovery.2022; 21(6): 417. CrossRef
Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients Antonio Gil-Gómez, Ángela Rojas, María R. García-Lozano, Rocío Muñoz-Hernández, Rocío Gallego-Durán, Douglas Maya-Miles, Rocío Montero-Vallejo, Sheila Gato, Javier Gallego, Rubén Francés, Germán Soriano, Javier Ampuero, Manuel Romero-Gómez International Journal of Molecular Sciences.2022; 23(19): 11840. CrossRef
Update on genetics and epigenetics in metabolic associated fatty liver disease Xiaopeng Zhu, Mingfeng Xia, Xin Gao Therapeutic Advances in Endocrinology and Metabolism.2022;[Epub] CrossRef
No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study Yuwei Liu, Hongqin Xu, ZiHan Zhao, Yutong Dong, Xiaomei Wang, Junqi Niu Frontiers in Microbiology.2022;[Epub] CrossRef
Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis Shan Tang, Jing Zhang, Ting-Ting Mei, Wen-Yan Zhang, Su-Jun Zheng, Hai-Bin Yu BMC Gastroenterology.2021;[Epub] CrossRef
An analysis of polygenic risk scores for non-alcoholic fatty liver disease Dae Won Jun Clinical and Molecular Hepatology.2021; 27(3): 446. CrossRef
First
Prev
